[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases].
In: Kardiologiia, Jg. 61 (2021-05-04), Heft 4, S. 66-72
academicJournal
Zugriff:
The article discusses issues of reducing the risk for cardiovascular diseases (CVDs) in patients with type 2 diabetes mellitus during the treatment with modern hypoglycemic drugs, specifically glucagon-like peptide-1 receptor agonists.
Titel: |
[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases].
|
---|---|
Autor/in / Beteiligte Person: | Gilarevsky, SR |
Zeitschrift: | Kardiologiia, Jg. 61 (2021-05-04), Heft 4, S. 66-72 |
Veröffentlichung: | <2017->: Moskva : OOO "Obshchestvo spet︠s︡ialistov po serdechnoĭ nedostatochnosti" ; <i>Original Publication</i>: Moskva., 2021 |
Medientyp: | academicJournal |
ISSN: | 0022-9040 (print) |
DOI: | 10.18087/cardio.2021.4.n1549 |
Schlagwort: |
|
Sonstiges: |
|